168 related articles for article (PubMed ID: 16258497)
1. Enhanced detection of hepatocellular carcinoma.
el-Houseini ME; Mohammed MS; Elshemey WM; Hussein TD; Desouky OS; Elsayed AA
Cancer Control; 2005 Oct; 12(4):248-53. PubMed ID: 16258497
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of squamous cell carcinoma antigen-immunoglobulin M complex (SCCA-IGM) and alpha-L-fucosidase (AFU) as novel diagnostic biomarkers for hepatocellular carcinoma.
Mossad NA; Mahmoud EH; Osman EA; Mahmoud SH; Shousha HI
Tumour Biol; 2014 Nov; 35(11):11559-64. PubMed ID: 25129443
[TBL] [Abstract][Full Text] [Related]
3. Alpha-L-fucosidase as a serum marker of hepatocellular carcinoma in Thailand.
Tangkijvanich P; Tosukhowong P; Bunyongyod P; Lertmaharit S; Hanvivatvong O; Kullavanijaya P; Poovorawan Y
Southeast Asian J Trop Med Public Health; 1999 Mar; 30(1):110-4. PubMed ID: 10695798
[TBL] [Abstract][Full Text] [Related]
4. Serological biomarkers of hepatocellular carcinoma in Egyptian patients.
El-Tayeh SF; Hussein TD; El-Houseini ME; Amer MA; El-Sherbini M; Elshemey WM
Dis Markers; 2012; 32(4):255-63. PubMed ID: 22430192
[TBL] [Abstract][Full Text] [Related]
5. Clinical performance of α-L-fucosidase for early detection of hepatocellular carcinoma.
Xing H; Qiu H; Ding X; Han J; Li Z; Wu H; Yan C; Li H; Han R; Zhang H; Li C; Wang M; Wu M; Shen F; Zheng Y; Yang T
Biomark Med; 2019 May; 13(7):545-555. PubMed ID: 31140827
[No Abstract] [Full Text] [Related]
6. Diagnostic value of 5 serum biomarkers for hepatocellular carcinoma with different epidemiological backgrounds: A large-scale, retrospective study.
Liu D; Luo Y; Chen L; Chen L; Zuo D; Li Y; Zhang X; Wu J; Xi Q; Li G; Qi L; Yue X; Zhang X; Sun Z; Zhang N; Song T; Lu W; Guo H
Cancer Biol Med; 2021 Feb; 18(1):256-270. PubMed ID: 33628599
[TBL] [Abstract][Full Text] [Related]
7. Serological tumor markers of hepatocellular carcinoma: a meta-analysis.
Hussein TD
Int J Biol Markers; 2015 Feb; 30(1):e32-42. PubMed ID: 25450646
[TBL] [Abstract][Full Text] [Related]
8. Value of circulating cell-free DNA in diagnosis of hepatocelluar carcinoma.
Chen K; Zhang H; Zhang LN; Ju SQ; Qi J; Huang DF; Li F; Wei Q; Zhang J
World J Gastroenterol; 2013 May; 19(20):3143-9. PubMed ID: 23716996
[TBL] [Abstract][Full Text] [Related]
9. Alpha-L-fucosidase as a tumour marker of hepatocellular carcinoma.
Fawzy Montaser M; Amin Sakr M; Omar Khalifa M
Arab J Gastroenterol; 2012 Mar; 13(1):9-13. PubMed ID: 22560818
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of transforming growth factor alpha and vascular endothelial growth factor in diagnosis of hepatocellular carcinoma.
El-Sherif WT; Makhlouf NA; El-Gendi SS; Hassan HI; Herdan OM
Egypt J Immunol; 2012; 19(2):53-65. PubMed ID: 23885407
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
[TBL] [Abstract][Full Text] [Related]
12. Influence of hepatitis C virus infection on circulating levels of sICAM-1 and VEGF in patients with hepatitis C and hepatocellular carcinoma (HCC) and their role in enhancing detection of HCC.
Helaly GF; Abou Shamaa LA
Egypt J Immunol; 2006; 13(1):27-38. PubMed ID: 17974148
[TBL] [Abstract][Full Text] [Related]
13. Serum insulin-like growth factor-II as a serologic marker of small hepatocellular carcinoma.
Tsai JF; Jeng JE; Chuang LY; You HL; Wang LY; Hsieh MY; Chen SC; Chuang WL; Lin ZY; Yu ML; Dai CY
Scand J Gastroenterol; 2005 Jan; 40(1):68-75. PubMed ID: 15841717
[TBL] [Abstract][Full Text] [Related]
14. [A preliminary study on serum alpha-L-fucosidase assay in the diagnosis of hepatocellular carcinoma].
Shen W; Shen DM
Zhonghua Nei Ke Za Zhi; 1989 Jul; 28(7):397-9, 442-3. PubMed ID: 2480210
[TBL] [Abstract][Full Text] [Related]
15. Serum insulin-like growth factor-II and alpha-fetoprotein as tumor markers of hepatocellular carcinoma.
Tsai JF; Jeng JE; Chuang LY; You HL; Ho MS; Lai CS; Wang LY; Hsieh MY; Chen SC; Chuang WL; Lin ZY; Yu ML; Dai CY
Tumour Biol; 2003; 24(6):291-8. PubMed ID: 15004489
[TBL] [Abstract][Full Text] [Related]
16. The role of chemokine CC ligand 20 in patients with liver cirrhosis and hepatocellular carcinoma.
Soliman HH; Nagy H; Kotb N; Alm El-Din MA
Int J Biol Markers; 2012 Jul; 27(2):e125-31. PubMed ID: 22388957
[TBL] [Abstract][Full Text] [Related]
17. Serum VEGF as a tumor marker in patients with HCV-related liver cirrhosis and hepatocellular carcinoma.
Mukozu T; Nagai H; Matsui D; Kanekawa T; Sumino Y
Anticancer Res; 2013 Mar; 33(3):1013-21. PubMed ID: 23482775
[TBL] [Abstract][Full Text] [Related]
18. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH
Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of annexin A2 and as potential biomarkers for hepatocellular carcinoma.
El-Abd N; Fawzy A; Elbaz T; Hamdy S
Tumour Biol; 2016 Jan; 37(1):211-6. PubMed ID: 26189841
[TBL] [Abstract][Full Text] [Related]
20. The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population.
Leerapun A; Suravarapu SV; Bida JP; Clark RJ; Sanders EL; Mettler TA; Stadheim LM; Aderca I; Moser CD; Nagorney DM; LaRusso NF; de Groen PC; Menon KV; Lazaridis KN; Gores GJ; Charlton MR; Roberts RO; Therneau TM; Katzmann JA; Roberts LR
Clin Gastroenterol Hepatol; 2007 Mar; 5(3):394-402; quiz 267. PubMed ID: 17368240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
